The new agreement comes at a time when GSK and CureVac have been at risk of falling behind in mRNA vaccines for respiratory diseases, with combined flu/COVID-19 candidates from Moderna and Pfizer ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster COVID-19 ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

The lawsuits specifically concern Moderna’s COVID-19 vaccine, Spikevax, and its more recently approved mRNA shot for respiratory syncytial virus (RSV), mRESVIA. GSK claims Moderna is marketing ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GSK PLC (GSK) reports robust year-to-date sales growth, driven by Specialty Medicines, while navigating vaccine sales ...

GSK filed a related lawsuit against Pfizer and BioNTech in the same court in April over their COVID-19 vaccine. The new litigation seeks unspecified monetary damages. A spokesperson for ...